For some medical conditions there are hundreds of bacteria shifts reported, for others only a few. The Percentage is based on the least number. If there are matches 8 matches for a condition that has 10 known bacteria shifts, against a condition that has 50 bacteria shifts. It will be 8/10 or 80% and not 8/50= 16%. The count of possible bacteria is shown for reference.
Limited to conditions with 5 or more bacteria
Name | Overlap Percent | Prevalance in Population | Matches | Bacteria in From | Bacteria in To |
---|---|---|---|---|---|
Allergies | 26 % | 30% | 13 | 50 | 108 |
Ankylosing spondylitis | 45.4 % | 7% | 49 | 520 | 108 |
Alzheimer's disease | 38 % | 10% | 19 | 50 | 108 |
Autism | 25 % | 2% | 27 | 110 | 108 |
Rosacea | 31.8 % | 5.46% | 7 | 22 | 108 |
Schizophrenia | 25.8 % | 0.75% | 24 | 93 | 108 |
Multiple Sclerosis | 25 % | 0.5% | 25 | 100 | 108 |
Mood Disorders | 66.7 % | 29.7% | 4 | 6 | 108 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 35.2 % | 0.86% | 38 | 134 | 108 |
Psoriasis | 45.7 % | 3% | 21 | 46 | 108 |
Obesity | 27.3 % | 42.4% | 15 | 55 | 108 |
Obesity | 26 % | 42.4% | 27 | 104 | 108 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 34.9 % | 0.005% | 15 | 43 | 108 |
Osteoporosis | 36.4 % | 9.4% | 8 | 22 | 108 |
neuropsychiatric disorders (PANDAS, PANS) | 33.3 % | 0.1% | 5 | 15 | 108 |
ME/CFS with IBS | 42.1 % | 2.8% | 8 | 19 | 108 |
ME/CFS without IBS | 26.9 % | 0.4% | 7 | 26 | 108 |
Multiple system atrophy (MSA) | 19 % | 0.005% | 4 | 21 | 108 |
Metabolic Syndrome | 57.1 % | 21% | 4 | 7 | 108 |
Systemic Lupus Erythematosus | 37.9 % | 0.15% | 25 | 66 | 108 |
Liver Cirrhosis | 54.6 % | 0.27% | 59 | 678 | 108 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 34.2 % | 25% | 26 | 76 | 108 |
Parkinson's Disease | 22.2 % | 1% | 20 | 90 | 108 |
Chronic Kidney Disease | 40 % | 15% | 14 | 35 | 108 |
Insomnia | 70 % | 30% | 7 | 10 | 108 |
Depression | 28.4 % | 8% | 23 | 81 | 108 |
Irritable Bowel Syndrome | 40.3 % | 15% | 25 | 62 | 108 |
Chronic Urticaria (Hives) | 65.2 % | 5% | 15 | 23 | 108 |
IgA nephropathy (IgAN) | 37.9 % | 0.001% | 11 | 29 | 108 |
Hyperlipidemia (High Blood Fats) | 20 % | 33% | 5 | 25 | 108 |
hypertension (High Blood Pressure | 16.7 % | 47% | 1 | 6 | 108 |
hypercholesterolemia (High Cholesterol) | 33.3 % | 12% | 3 | 9 | 108 |
Allergic Rhinitis (Hay Fever) | 19.4 % | 7.8% | 7 | 36 | 108 |
gallstone disease (gsd) | 46.7 % | 5% | 7 | 15 | 108 |
Graves' disease | 12.5 % | 0.5% | 1 | 8 | 108 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 29.2 % | 27.8% | 7 | 24 | 108 |
Fibromyalgia | 32.4 % | 1.12% | 12 | 37 | 108 |
Functional constipation / chronic idiopathic constipation | 26.8 % | 14% | 11 | 41 | 108 |
Type 1 Diabetes | 30.8 % | 0.19% | 16 | 52 | 108 |
Gout | 19 % | 6.8% | 4 | 21 | 108 |
Epilepsy | 40 % | 0.84% | 10 | 25 | 108 |
Cerebral Palsy | 52.9 % | 0.2% | 9 | 17 | 108 |
Inflammatory Bowel Disease | 43.9 % | 1.3% | 29 | 66 | 108 |
Celiac Disease | 31.3 % | 1.4% | 21 | 67 | 108 |
cystic fibrosis | 14.3 % | 0.03% | 1 | 7 | 108 |
COVID-19 | 41.7 % | 50% | 15 | 36 | 108 |
Carcinoma | 43.1 % | 1% | 22 | 51 | 108 |
Bipolar Disorder | 54.5 % | 3% | 18 | 33 | 108 |
Colorectal Cancer | 21.3 % | 4.3% | 23 | 296 | 108 |
Chronic Fatigue Syndrome | 25.5 % | 3% | 14 | 55 | 108 |
Coronary artery disease | 31.3 % | 6.7% | 5 | 16 | 108 |
Crohn's Disease | 44.4 % | 0.3% | 48 | 141 | 108 |
Generalized anxiety disorder | 35.7 % | 2.7% | 5 | 14 | 108 |
Asthma | 33.3 % | 8% | 9 | 27 | 108 |
Atherosclerosis | 39.8 % | 50% | 43 | 524 | 108 |
Acne | 63.2 % | 47% | 12 | 19 | 108 |
Stress / posttraumatic stress disorder | 55.4 % | 5.2% | 31 | 56 | 108 |
Small Intestinal Bacterial Overgrowth (SIBO) | 43.8 % | 52% | 7 | 16 | 108 |
Brain Trauma | 31.8 % | 0.367% | 7 | 22 | 108 |
Sjögren syndrome | 34.1 % | 1.2% | 14 | 41 | 108 |
Type 2 Diabetes | 55.6 % | 10.8% | 60 | 267 | 108 |
ADHD | 25.5 % | 9.4% | 12 | 47 | 108 |
Hashimoto's thyroiditis | 35.7 % | 0.35% | 5 | 14 | 108 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 ยงโฏ1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.